BioMarin Pharmaceutical Inc. $BMRN Shares Sold by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. cut its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 45.4% during the third quarter, HoldingsChannel reports. The fund owned 222,720 shares of the biotechnology company’s stock after selling 185,495 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in BioMarin Pharmaceutical were worth $13,363,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in BMRN. Primecap Management Co. CA purchased a new position in BioMarin Pharmaceutical in the second quarter worth approximately $811,962,000. Dimensional Fund Advisors LP raised its position in BioMarin Pharmaceutical by 14.5% in the first quarter. Dimensional Fund Advisors LP now owns 3,802,930 shares of the biotechnology company’s stock valued at $214,804,000 after purchasing an additional 481,176 shares during the period. First Trust Advisors LP raised its position in BioMarin Pharmaceutical by 43.3% in the first quarter. First Trust Advisors LP now owns 1,672,491 shares of the biotechnology company’s stock valued at $94,479,000 after purchasing an additional 505,692 shares during the period. Caisse de depot et placement du Quebec purchased a new stake in BioMarin Pharmaceutical in the second quarter valued at $70,749,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of BioMarin Pharmaceutical in the 2nd quarter valued at $66,107,000. 98.71% of the stock is currently owned by hedge funds and other institutional investors.

BioMarin Pharmaceutical Stock Performance

NASDAQ:BMRN opened at $55.95 on Friday. BioMarin Pharmaceutical Inc. has a fifty-two week low of $49.26 and a fifty-two week high of $70.98. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.32 and a current ratio of 2.39. The company has a 50 day moving average price of $61.70 and a 200 day moving average price of $58.65. The stock has a market capitalization of $10.83 billion, a P/E ratio of 33.71, a PEG ratio of 0.46 and a beta of 0.22.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.25. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%. The company had revenue of $989.71 million for the quarter, compared to analyst estimates of $932.03 million. During the same quarter in the previous year, the company earned $1.44 earnings per share. The firm’s quarterly revenue was up 20.0% compared to the same quarter last year. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Equities research analysts forecast that BioMarin Pharmaceutical Inc. will post 3.46 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on BMRN shares. Canaccord Genuity Group increased their price target on BioMarin Pharmaceutical from $111.00 to $114.00 and gave the stock a “buy” rating in a report on Monday, August 10th. Jefferies Financial Group raised their price objective on BioMarin Pharmaceutical from $104.00 to $105.00 and gave the stock a “buy” rating in a research report on Monday, August 31st. Weiss Ratings lowered shares of BioMarin Pharmaceutical from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, September 18th. Barclays upped their target price on shares of BioMarin Pharmaceutical from $111.00 to $114.00 and gave the company an “overweight” rating in a research report on Wednesday, October 14th. Finally, Morgan Stanley decreased their target price on shares of BioMarin Pharmaceutical from $124.00 to $122.00 and set an “overweight” rating on the stock in a research report on Wednesday. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, BioMarin Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average price target of $88.60.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.